These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements. Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092 [TBL] [Abstract][Full Text] [Related]
24. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S J BUON; 2015; 20(3):820-8. PubMed ID: 26214636 [TBL] [Abstract][Full Text] [Related]
25. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576 [TBL] [Abstract][Full Text] [Related]
26. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Petrich AM; Nabhan C; Smith SM Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588 [TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Akyurek N; Uner A; Benekli M; Barista I Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394 [TBL] [Abstract][Full Text] [Related]
28. [The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma]. Li M; Zhang QL; Zhao W; Huang X; Gong LP; Shi QF; Liu CL; Gao ZF Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):124-128. PubMed ID: 33858042 [No Abstract] [Full Text] [Related]
29. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384 [TBL] [Abstract][Full Text] [Related]
30. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538 [TBL] [Abstract][Full Text] [Related]
31. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci. Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005 [TBL] [Abstract][Full Text] [Related]
32. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation. Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190 [TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234 [TBL] [Abstract][Full Text] [Related]
34. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782 [TBL] [Abstract][Full Text] [Related]
35. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas. Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453 [TBL] [Abstract][Full Text] [Related]
36. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs. Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R; Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318 [TBL] [Abstract][Full Text] [Related]
37. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157 [TBL] [Abstract][Full Text] [Related]
39. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026 [TBL] [Abstract][Full Text] [Related]
40. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]